MTOR and renal cell carcinoma: High levels of SELENOM were associated with poor prognosis of renal cell carcinoma (RCC), and preclinical evidence demonstrated that SELENOM silencing was able to block cancer proliferation, invasion, migration, and tumorigenesis, via PI3K/AKt/mTOR pathway inhibition and reduced metalloproteinases (MMP) 2 and 9 expression [13].